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ABSTRACT:
Background: Bevacizumab and temsirolimus are active agents in gynecologic 
tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance 
mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, 
commonly aberrant in these tumors
Patients and Methods: We analyzed safety and responses in 41 patients 
with gynecologic cancers treated as part of a Phase I study of bevacizumab and 
temsirolimus.  
Results: Median age of the 41 women was 60 years (range, 33-80 years); median 
number of prior systemic therapies was 4 (1-11). Grade 3 or 4 treatment-related 
toxicities included: thrombocytopenia (10%), mucositis (2%), hypertension (2%), 
hypercholesterolemia (2%), fatigue (7%), elevated aspartate aminotransferase (2%), 
and neutropenia (2%). Twenty-nine patients (71%) experienced no treatment-related 
toxicity greater than grade 2. Full FDA-approved doses of both drugs (bevacizumab 
15mg/kg IV Q3weeks and temsirolimus 25mg IV weekly) were administered without 
dose-limiting toxicity. Eight patients (20%) achieved stable disease (SD) ≥ 6 months 
and 7 patients (17%), a partial response (PR) [total = 15/41 patients (37%)]. Eight 
of 13 patients (62%) with high-grade serous histology (ovarian or primary peritoneal) 
achieved SD ≥ 6 months/PR.  
Conclusion: Bevacizumab and temsirolimus was well tolerated. Thirty-seven 
percent of heavily-pretreated patients achieved SD ≥ 6 months/PR, suggesting that 
this combination warrants further study. 
INTRODUCTION
Angiogenesis plays a key role in the pathogenesis 
of metastases, as new vessels provide growing tumors 
with nutrients, growth factors, oxygen, proteolytic 
enzymes, hemolytic factors, and hormones [1-3]. The 
vascular endothelial growth factor (VEGF) family of 
proteins and receptors is important in tumor angiogenesis 
and fundamental for tumor growth and metastasis [4, 5].  
Bevacizumab is a monoclonal antibody specific for VEGF 
and prevents VEGF from interacting with its receptors on 
the surface of endothelial cells [6]. Bevacizumab inhibits 
angiogenesis, reducing tumor microvascularity and 
abrogating metastatic disease progression [6-8]. 
Diverse receptors in interconnected signaling 
pathways communicate with each other through cross-talk 
[9, 10]. Because communication is not restricted to a single 
receptor or signaling pathway, tumors frequently become 
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resistant to antiangiogenic therapy through mechanisms 
such as upregulation of hypoxia-inducible factor (HIF)-1 
α [3, 7, 11-21]. Adaptive responses to hypoxic conditions 
are modulated through HIF-1α over-expression, increasing 
levels of VEGF, which results in aggressive tumor growth 
and poor patient outcomes [3, 7, 11-21].  
Temsirolimus is an inhibitor of mammalian target of 
rapamycin (mTOR), a serine/threonine kinase involved in 
initiating messenger ribonucleic acid (mRNA) translation 
[22, 23]. Aberrations of the phosphatidylinositol 3 (PI3)-
kinase/AKT/mTOR pathway are common in several 
gynecologic malignancies such as endometrial and 
ovarian cancer [24, 25]. Renal cell carcinoma cell lines 
demonstrated inhibition of mTOR activity in in vitro 
studies with temsirolimus, as well as reduced levels 
of HIF-1α, HIF-2α and VEGF [21]. Temsirolimus also 
inhibited VEGF production in vitro under both normoxic 
and hypoxic conditions through inhibition of HIF-1 
expression and transcriptional activation in the human 
epidermal growth factor receptor (HER)-2 gene amplified 
breast cancer cell line BT474 [26].
Taken together, there are several compelling 
rationales for combining bevacizumab and temsirolimus 
in gynecologic tumors: i) temsirolimus inhibits mTOR and 
the PI3 kinase/AKT/mTOR pathway is critical in several 
gynecologic malignancies [24, 25]; ii) temsirolimus 
attenuates upregulation of HIF-1α levels, which may be 
a resistance mechanism for bevacizumab [21, 26]; iii) 
single-agent activity with temsirolimus and bevacizumab 
have been demonstrated in gynecologic cancers [27, 28]; 
and, iv) the two agents have non-overlapping toxicities. 
Here we report our experience treating patients with 
gynecologic malignancies with this combination therapy.
RESULTS
Demographic and Clinical Characteristics 
Forty-one women with advanced, metastatic ovarian, 
uterine and cervical malignancies were enrolled starting in 
April 2008. Demographic and clinical characteristics are 
summarized in Table 1. The median age of patients was 60 
years (range, 33-80 years). The most common cancer sites 
were ovarian followed by uterine. The median number of 
prior systemic therapies was 4 (range, 1-11). All patients 
had experienced disease progression on their prior therapy. 
No patients had received prior mTOR inhibitor therapy. 
Fourteen of forty-one patients (34%) had received prior 
therapy with bevacizumab. The median number of cycles 
(cycle = 21 days) completed for all patients was 4 (range, 
1-25+). Thirty-four patients (83%) received more than 2 
cycles. For patients with SD or better, the median number 
of cycles completed was 12 (range, 6-25+). At the time of 
analysis, three patients were continuing on therapy. 
Table 1: Baseline Demographics and Clinical 
Characteristics
Characteristic Total (%)
Number of patients 41
Age, years  
     Median (Range) 60 (33-80)
Number of prior systemic therapies
     Median (Range) 4 (1-11)
ECOG performance status*  
0 10 (24)
1 25 (61)
2 6 (15)
Prior treatment  
     Surgery 39 (95)
     Radiation 18 (44)
     Chemotherapy 41 (100)
     Phase I trial 5 (12)
    Temsirolimus 0 (0)
    Bevacizumab 14 (34)
Primary Organ Site  
     Fallopian Tube 1 (2)
     Vagina 1 (2)
     Ovarian 22 (54)
              High grade serous^ 13 (32)
              Low grade serous 1 (2)
              Endometroid# 2 (5)
              Clear Cell 3 (7)
              Transitional Cell 1 (2)
              Undifferentiated 1 (2)
              Carcinoma, Mullerian# 1 (2)
     Uterus 11 (27)
               Epithelial 9 (22)
               Carcinosarcoma 1 (2)
               Clear Cell 1 (2)
      Cervix 6 (15)
               Squamous 4 (10)
               Adenocarcinoma 1 (2)
               Neuroendocrine 1 (2)
* ECOG = Eastern Cooperative Oncology Group
 ^ includes two patients with peritoneal disease
# includes one patient with peritoneal disease
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Toxicity Assessment
Patients were enrolled in accordance with the 
planned 3+3 study design until dose level 11 (Table 2), at 
which point an expansion cohort for response (as described 
in the Methods section) was initiated. Dose escalation for 
the remaining two levels continued in accordance with the 
original dose escalation plan. Dose level 13 (bevacizumab 
15 mg/kg and temsirolimus 25 mg) was reached and no 
MTD was obtained as we were able to reach the highest 
FDA-approved doses of both drugs (29). 
 All 41 patients with an advanced gynecologic 
malignancy experienced at least one adverse event that 
was possibly drug related. These events were mostly 
grade 1 or grade 2 and reversible. In fact, 29 patients 
(71%) experienced no treatment-related toxicity greater 
than grade 2. Grade 3 or 4 toxicities were as follows: 
thrombocytopenia (10%), mucositis (2%), hypertension 
(2%), hypercholesterolemia (2%), fatigue (7%), elevated 
aspartate aminotransferase (2%), and decreased absolute 
neutrophil count/leucopenia (2%). Among this subset of 
patients, two DLTs occurred (grade 3 hypertension at dose 
level 3 (bevacizumab 15 mg/kg and temsirolimus 5 mg) 
and grade 3 fatigue at dose level 13 (bevacizumab 15 mg/
kg and temsirolimus 25 mg)) (Table 2). These toxicities 
were reversible when the dose was lowered or held. Of 
the 25 patients treated at the MTD, only 3/25 (12%) were 
dose-reduced for toxicities occurring during the first 
cycle. In these three instances, the temsirolimus was dose 
reduced from 25 to 20 mg. The causes of dose reduction 
were grade 3 fatigue (n=1), grade 2 mucositis (n=1) and 
Table 2: Dose-Escalation Schedule (21-day cycle), Grade 3/4 Toxicities* and Response 
Dose 
Level 
Temsirolimus IV on 
Days 1, 8 and 15
Bevacizumab IV on 
Day 1
SD≥6 months/PR 
Total Treated Grade (G) 3/4 Toxicity (N)*
1-3 5 mg 5, 10 and 15 mg/kg 2/6
G3 HTN (1)^; 
G3 Hypercholesterolemia (1)
All at 15 mg/kg of bevacizumab
4-6 12.5 mg 2.5, 7.5 and 15  mg/kg 2/3
G3 Neutropenia (1); 
G3 Elevated Aspartate Aminotransferase
All at 15 mg/kg of bevacizumab
7-9 20 mg 2.5. 7.5 and 15  mg/kg 1/3 G3 Thrombocytopenia (1)at 15 mg/kg of bevacizumab 
10-13 25 mg 2.5, 5, 10, 15 mg/kg 10/29
G4 Thrombocytopenia (1);
G3 Fatigue (3)^; 
G3 Mucositis (1); 
G3 Thrombocytopenia (1); 
G4 Thrombocytopenia (1)
All at 10 or 15 mg/kg bevacizumab
* Adverse events deemed at least possibly related to treatment were graded based on the Common Terminology Criteria for Adverse Events, version 3.0 
(CTCAEv3.0)
^was defined as a dose-limiting toxicity
Abbreviations:  N, number of patients experiencing toxicity
Table 3: Tumor Molecular Analysis
Tumor Molecular Analysis Response Comments
 Total (%)  
K-RAS Mutation   
Number Tested: 17  
Number with 
Mutation: 1 (6%)
KRAS mutation positive 
patient did not achieve 
SD ≥ 6 months/PR
N-RAS Mutation   
Number Tested: 17  
Number with 
Mutation: 1 (6%)
NRAS mutation positive 
patient did not achieve 
SD ≥ 6 months/PR
B-RAF Mutation   
Number Tested: 15  
Number with 
Mutation: 0  
PI3 Kinase 
Mutation   
Number Tested: 25  
Number with 
Mutation: 1 (4%)
PI3 Kinase mutation 
positive patient achieved 
a PR
PTEN Loss   
     Number 
Tested: 2  
     Number with 
Loss: 0  
Abbreviations:  PR, partial response; SD, stable disease 
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grade 2 diarrhea (n=1).
There were no gastrointestinal perforations, 
thromboembolic events or cases of significant proteinuria. 
Two patients experienced gastrointestinal-vaginal fistula. 
One patient had vaginal cancer (adenocarcinoma) and 
had received prior pelvic radiation. She had a history of 
gastrointestinal-vaginal fistula prior to protocol entry and 
had been surgically diverted with colostomy. While on 
therapy, she developed worsening vaginal discharge and 
perineal pain. Though there was no radiographic evidence 
on computed-tomography (CT) scans of the abdomen/
pelvis of fistula, clinically she was believed to have 
gastrointestinal-vaginal fistula (grade 2). She completed 
only one cycle of therapy before withdrawing consent. 
The second patient had low grade serous ovarian cancer 
with no prior history of pelvic radiation. She was found 
on CT of the abdomen and pelvis to have gastrointestinal-
vaginal fistula (grade 1). She was taken off protocol for 
fistula formation and received only one cycle of therapy. 
Finally there was one patient who developed wound 
healing complications. This patient had cervical cancer 
(squamous cell) and a history of prior radiation. She had 
undergone vaginoplasty with subsequent development 
of recto-vaginal fistula and necrotic tumor in the vagina. 
Her vaginal mass decreased in size by 28% per RECIST 
on the first restaging but her course was complicated by 
persistent perirectal abscess treated with oral antibiotics. 
The abscess remained stable during her three cycle of 
treatment; however, the patient was taken off protocol as 
she wished to pursue elective colostomy. 
Antitumor Activity
Thirty-four of the 41 patients had disease that 
was measurable by RECIST and reached restaging. All 
patients, however, were considered evaluable. Figure 1 is 
a waterfall plot depicting best response by patient. Five 
patients were assigned an arbitrary value of +21% for 
early clinical progression or new lesions upon restaging. 
The remaining two patients were assigned a value of +1% 
as they were evaluable but not measurable by RECIST and 
had SD. Seven patients (17%) achieved a partial response 
(PR). SD lasting ≥ 6 months was observed in 8 patients 
(20%). The total SD ≥ 6 months/PR rate was 15/41 
patients (37%). Details regarding these patients including 
dose level, duration of treatment and best response by 
RECIST are described in Table 4. 
The only patient with clear cell carcinoma of the 
uterus achieved a PR. Of 11 patients with cancer arising 
from the uterus, four (36%) had SD ≥ 6 months or a PR 
(these included 3/9 patients with epithelial uterine cancer 
and 1/1 patient with clear cell carcinoma). Among 11 
patients with high-grade serous ovarian cancer, three 
Figure 1: Waterfall Plot Depicting Best RECIST Response by Patient. Individual patients/disease sites are represented by 
vertical bars on the X-axis. The best RECIST response (%) is depicted on the Y-axis. Thirty-four of the 41 patients were measurable by 
RECIST.  Five patients were assigned a value of +21% for clinical progression or new lesions (+). Two patients were assigned a value of 
+1% as they were evaluable but not measurable by RECIST and had stable disease (*). Dotted line shows 30% response by RECIST.
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(27%) achieved a PR and three (27%) attained prolonged 
SD ≥ 6 months (total = 6/11 (55%) with SD ≥ 6 months/
PR). Among four patients with primary peritoneal disease, 
the two patients with high grade serous histology achieved 
SD ≥ 6 months. Among four patients with squamous cell 
carcinoma of the cervix, two (50%) achieved a PR. Finally, 
one patient with fallopian tube cancer achieved prolonged 
SD (≥ 6 months). Characteristics of the responders are 
detailed in Table 5.
There was no obvious dose-response relationship. 
Three of 7 patients (43%) treated on dose levels 1 through 
5 achieved SD≥6 months/PR versus 12 of 34 patients 
(35%) on dose levels 6 through 13 (P = 0.7). Six of 16 
patients (38%) at dose levels 1 through 12 achieved SD≥6 
months/PR versus 9 of 25 patients (36%) at dose level 13 
(p = 1).
Molecular Analysis and Association with Response
When archival cell blocks for patients were 
available, CLIA-certified testing was performed for BRAF, 
NRAS, KRAS, and PI3 kinase mutations along with 
evaluation for PTEN loss. PI3 kinase mutational status 
was known for 25/41 of patients (61%) and was positive 
in one (45%). This patient achieved a PR. PTEN status 
was known for 2/41 (5%), and PTEN loss was identified 
in none of the patients tested. For BRAF, mutational status 
was evaluated in 15/41 (37%) and was positive in none 
of the patients tested. Finally, KRAS/NRAS mutations 
were evaluated in 17/41 of the patients (41%). One patient 
(6%) had an NRAS mutation and 1 (6%) patient had a 
KRAS mutation. Neither of these patients achieved SD ≥ 
6 months or a PR (Table 3). Among the 15 patients with a 
Table 4: Stable Disease > 6 months or Partial Response (PR) by RECIST and Characterization by Patient
Disease Site Histology Dose Level
Best 
Response
# of Prior 
Cytotoxic 
Regimens
Duration of 
Treatment 
(weeks)
PTEN*
PI3K 
Mutation
RAS 
Mutation
RAF 
Mutation
Uterus Clear Cell Carcinoma 5 -39% 3 36 ND Y ND N
Ovary High Grade Serous 13 -33% 4 27 ND N N N
Cervix Squamous 6 -43% 3 18 ND N ND ND
Ovary High Grade Serous 13 -59% 7 63+ ND N ND N
Uterus Epithelial 13 -38% 4 21 P N N ND
Ovary High Grade Serous 13 -50% 2 48 ND ND ND ND
Cervix Squamous 13 -68% 1 60+ ND ND ND ND
Peritoneum
High Grade
Serous 2 0% 4 24 ND N ND ND
Ovary High Grade Serous 3 -7% 5 36 ND N ND ND
Uterus Epithelial 8
Non-
measurable 
by RECIST
1 36 ND N N ND
Ovary High Grade Serous 12 -28% 4 36 ND ND ND ND
Fallopian 
Tube Epithelial 13 -17% 3 36 ND N N N
Peritoneum
High Grade 
Serous 13 -19% 5 30 ND N N N
Uterus Epithelial 13
Non-
measurable 
by RECIST
2 75+ P ND N N
Ovary High Grade Serous 13 -29% 6 24 ND ND ND ND
Abbreviations:  ND, not done; N, no; Y, yes; P, present
*PTEN is tested by immunohistochemistry; absence of PTEN generally indicates an aberration 
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SD ≥ 6 months/PR, 10 patients (67%) were tested for PI3 
kinase mutations and only one was positive. Two patients 
were tested for PTEN loss (one of whom was also tested 
for PIK3CA mutation) and neither was positive.
DISCUSSION
There is a paucity of definitive data regarding 
optimal therapy in patients with advanced gynecologic 
malignancies after failure of first-line agents. Many of 
these patients are heavily pretreated, and thus less likely to 
tolerate full-dose cytotoxic therapy. In our study, treatment 
with bevacizumab and temsirolimus showed excellent 
tolerance even when the maximum FDA-approved dose 
of each drug was used in the combination. Twenty-nine 
patients (71%) experienced no treatment-related toxicity 
greater than grade 2 and only two DLTs were observed. 
A minority of patients (n=12) experienced grade 3 or 4 
toxicities, most of which were cytopenias, dyslipidemia, 
elevated liver function tests (AST) or fatigue, and 
attributed to temsirolimus. These toxicities were reversible 
with discontinuation of treatment or lowering of the dose, 
and were mostly managed with supportive care while 
patients were on therapy. Further, we had no complications 
of gastrointestinal perforation, significant proteinuria or 
thromboembolic events. One patient developed a new 
gastro-vaginal fistula on therapy. One patient with wound 
healing complications from prior vaginoplasty and locally 
advanced necrotic vaginal tumor, had shrinkage of her 
vaginal tumor (-28%) at first restaging and was taken 
off study because she wished to proceed with elective 
colostomy.
Moroney et al [39] recently reported a SD ≥ 6 
months/PR/CR rate of 38% in patients with advanced 
gynecologic and breast malignancy treated with liposomal 
doxorubicin, bevacizumab and temsirolimus. Our SD ≥ 
6 months/PR rate was 37% which is comparable without 
the added toxicity of liposomal doxorubicin. Our patients, 
like those reported by Moroney et al [39], were heavily 
pretreated with a median of four prior systemic therapies. 
Table 5: Response Data by Disease Site and Histology
Disease Site/Histology # of patients treated PR
SD≥ 6 
months
Median Number of cycles 
completed (range)
Uterus 11   6 (2-25+)
      Epithelial 9 1 2 5 (2-25+)
      Carcinosarcoma 1   6
      Clear Cell 1 1  12
Ovary 18   4 (1-21+)
      High grade serous 11 3 3 8 (1-21+)
      Low grade serous 1   1
      Endometroid 1   2
      Clear Cell 3   4 (3-5)
      Transitional Cell 1   1
      Undifferentiated 1   4
Peritoneum 4   4.5 (1-10)
      High grade serous 2  2 9 (8-10)
      Carcinoma, Mullerian 1   1
      Endometroid 1   1
Cervix 6   4.5 (1-20+)
       Squamous 4 2  4.5 (1-20+)
       Adenocarcinoma 1   6
       Neuroendocrine 1   2
Fallopian Tube 1    
       Epithelial 1  1 12
Vagina 1    
       Adenocarcinoma 1   1
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However, 51/74 patients (69%) of the patients treated by 
Moroney et al [39] experienced any tumor regression, 
while only 18/41 patients (44%) of our patients did. Only 
a randomized study would be able to answer the question 
as to whether or not liposomal doxorubicin adds activity 
to the bevacizumab and temsirolimus regimen.
Mutations in PI3 kinase result in activation of 
the PI3 kinase/AKT/mTOR pathway and are present 
in various tumor types [40, 41]. In gynecologic 
malignancies, phosphoinositide-3-kinase, catalytic, alpha 
polypeptide (PIK3CA) mutations are found in 23%, 10% 
and 12% of endometrial, ovarian, and cervical cancers, 
respectively[42]. PTEN typically acts as a repressor of 
the PI3 kinase/AKT/mTOR pathway and its loss results 
in its constitutive activation [43]. PTEN mutations are 
found in 40%, 4%, and 5% of endometrial, ovarian, 
and cervical cancers, respectively [42]. We previously 
reported a PR rate of 35% in heavily pretreated patients 
with diverse cancers and somatic PI3 kinase mutations 
treated with PI3kinase/AKT/mTOR pathway inhibitors 
[44]. In addition, Janku and colleagues [45] also showed 
a PR rate of 30% in patients with breast and gynecologic 
malignancies harboring PIK3CA mutations and treated 
with relevant pathway inhibitors. The relationship between 
mutational status and response in our patients is unclear 
because of the limited numbers of patients with tissue 
available for testing. Twenty-five of 41 patients (61%) 
were analyzed for PIK3CA mutation and only one was 
positive. This patient achieved a PR. Of the 24 patients 
who were negative for PIK3CA mutation, 9 patients (38%) 
achieved SD ≥ 6 months/PR. Further, of the 15 patients 
who achieved SD ≥ 6 months/PR, only 10 had a known 
PIK3CA mutation status. While these results suggest 
that PIK3CA mutations are not necessary to achieve 
SD ≥ 6 months/PR, there are several limitations to this 
observation. For example, our laboratory only evaluated 
exons 9 and 20 at the time of patient testing. These exons 
code only for the helical and kinase functional domains 
of PIK3CA, respectively. Mutations in the p85 binding 
site, RAS binding site and C2 region were not assessed 
so that other PI3 kinase mutations may have been missed. 
Further, aberrations in mTOR and AKT, though known 
to exist in cancer [46-48], were not assessed. Finally, 
PTEN loss and/or mutation are common in endometrial 
cancers [49] and merit more extensive evaluation. 
Unfortunately, limited tissue availability resulted in PTEN 
IHC testing being evaluated in only a small number of 
our patients. Of interest in this regard, Moroney et al 
[39] demonstrated that 13 of 25 patients (52%) with 
gynecologic malignancies that had PIK3CA mutations or 
PTEN loss and were treated with liposomal doxorubicin, 
bevacizumab, and temsirolimus achieved SD ≥ 6 months/
PR/CR. Further, the combination of bevacizumab and 
temsirolimus has shown preliminary evidence of activity 
in other tumors in which activation of the PI3 kinase/
AKT/mTOR axis has been implicated, including salivary 
duct tumors [50] and lymphangioleiomyomatosis [51]. 
Other mechanisms for response could be 
operative in our patients. For example, bevacizumab 
has antiangiogenic properties, and resistance to this 
agent is caused in part by upregulation of HIF-1α [3, 7, 
11-21]. Further, temsirolimus abrogates HIF-1α mRNA 
transcription and this may drive response in some patients 
[26]. 
There are several limitations to this study. First, 
molecular analysis could not be performed in many 
of the patients because of lack of tissue and therefore a 
biomarker was not elucidated. Second, these patients were 
heavily pretreated, with a median of four prior systemic 
therapies, and this may have limited response signals. 
Third, patients were treated on a variety of dose levels. 
However, in relation to the latter point, it should be noted 
that there was no obvious dose-response relationship, 
with SD≥6 months/PR attained even at dose levels 1 and 
2, and no difference in rate of SD≥6 months/PR in patients 
treated at the highest dose level (9 of 25 patients (36%)) 
versus those treated at lower dose levels (6 of 16 (38%)) (p 
= 1). However, the study was not designed to answer the 
dose-response question in a definitive manner. 
In conclusion, the combination of bevacizumab 
and temsirolimus was well tolerated in our study and has 
demonstrated clinical activity in patients with advanced 
gynecologic malignancy having undergone extensive 
prior therapy. The overall rate of SD ≥ 6 months/PR was 
37%, and 8 of 13 patients (62%) with high-grade serous 
histology (ovarian or primary peritoneal) achieved SD ≥ 
6 months/PR. Further study of this combination in larger 
populations with gynecologic cancers is warranted.
PATIENTS AND METHODS
Study Design and Dosing
The experience with gynecologic malignancies 
reported is part of a single institution, phase I, open-label, 
dose-escalation study. This trial was open to all patients 
with advanced or metastatic cancer refractory to standard 
therapy, relapsed after standard therapy, or who had no 
standard therapy available that improves survival by at 
least three months. (The trial successfully completed dose 
escalation to the highest specified dose level, that is dose 
level 13, which consisted of the highest FDA-approved 
doses of both drugs (bevacizumab 15 mg/kg IV every 3 
weeks and temsirolimus 25 mg IV weekly)[29].) 
Treatment was administered on an outpatient basis 
at MD Anderson Cancer Center. A cycle of therapy was 21 
days. No investigational or commercial agents or therapies 
other than those described here could be administered with 
the intent to treat the patient’s malignancy. Bevacizumab 
was given on day 1 only of each cycle while temsirolimus 
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was given weekly on days 1, 8 and 15 (Table 2). Restaging 
scans were performed after every two cycles. Consent 
was obtained and patients were treated in accordance with 
MD Anderson Cancer Center Institutional Review Board 
guidelines.
The protocol followed a standard 3+3 design. If 
one patient in a cohort experienced a DLT during the first 
cycle, three additional patients were enrolled and treated 
at that dose level. If at any time more than 33% of patients 
in a cohort experienced a DLT, that cohort was closed to 
additional patients. Adverse events were graded based on 
the Common Terminology Criteria for Adverse Events, 
version 3.0 (CTCAEv3.0) [30]. DLTs were defined as 
any grade three or four non-hematologic toxicity that was 
possibly, probably or definitely related to any of the study 
medications, with the following exceptions: a) any grade 
four hematologic toxicity lasting less than two weeks, and 
b) any grade four nausea or vomiting lasting less than five 
days. DLTs had to occur within the first cycle of treatment.
Of note, early in the trial multiple significant responses 
were observed. If a response was observed in a particular 
tumor type with the study drug combination, expanded 
enrollment was permitted for up to a total of 14 patients 
with that tumor type at the highest dose level deemed safe 
at the time of patient enrollment. All enrolled participants 
with that tumor type were considered in the DLT analysis. 
For the purpose of dose expansion, a tumor response was 
defined as one or more of the following: 1) stable disease 
for more than or equal to four months (SD ≥ 4 months), 2) 
decrease in the sum of target lesions by more than or equal 
to 20% by RECIST criteria 1.0, or 3) decrease in tumor 
markers by more than or equal to 25%. This resulted in 
cohort expansions in gynecologic malignancies.
Eligibility Criteria
Key inclusion criteria were histologically-
documented, advanced or metastatic solid tumors 
refractory to standard treatment or for which no standard 
therapy was available; Eastern Cooperative Oncology 
Group (ECOG) performance status ≤ two; absolute 
neutrophil count ≥ 1 x 109/L; platelet count ≥ 50.0 x 109/L; 
serum creatinine < 3.0 mg/dL, alanine transferase (ALT) ≤ 
five times the upper limit of normal (ULN); bilirubin ≤ 3.0 
mg/dL, total cholesterol < 350 mg/dL; and, triglyceride 
<400 mg/dL. Key exclusion criteria were clinically 
significant, unexplained bleeding or hemoptysis within 28 
days prior to study entry; poorly controlled hypertension 
(systolic blood pressure ≥ 140 mm Hg, diastolic pressure 
≥ 90 mm Hg); patients with clinically significant 
cardiovascular disease; and, pregnancy. Prior exposure to 
mTOR and VEGF-inhibitors were not exclusion criteria 
for study entry, nor were patients with a history of venous 
thromboembolism excluded.
Assessment of Tumor Response
Tumor measurements were performed on patients 
with measurable disease pre-treatment and every two 
cycles thereafter. Measurable target lesions were evaluated 
for response using Response Evaluation Criteria in Solid 
Tumors (RECIST 1.0) [31, 32]. For purposes of this report, 
prolonged stable disease (SD) was defined as lasting ≥ 6 
months.
Molecular Analysis (PIK3CA, BRAF, NRAS and 
KRAS, BRAF and PTEN)
PIK3CA, BRAF, NRAS and KRAS mutations were 
investigated in archival formalin-fixed, paraffin-embedded 
tissue blocks. DNA was extracted from microdissected 
paraffin-embedded tumor sections and analyzed using a 
polymerase chain reaction (PCR)-based DNA sequencing 
method for PIK3CA mutations in codons [c]532-554 
of exon 9 (helical domain) and c1011-1062 of exon 20 
(kinase domain)[33], which included the mutation hot 
spot region of the PIK3CA proto-oncogene by Sanger 
sequencing following amplification of 276 bp and 198 
bp amplicons, respectively. Codons 12, 13, and 61 were 
examined for KRAS and NRAS mutations and for BRAF, 
codons 468-474, codons 595-600, and mutations of exon 
15 by pyro-sequencing were examined as previously 
described [34]. PTEN loss by IHC generally indicates 
aberrant or mutated PTEN, which serves to activate the 
PI3 kinase/AKT/mTOR pathway [35-38]. Formalin-fixed 
paraffin-embedded sections (5 µm thick) from biopsy 
or resection specimens were used for IHC analysis. The 
sections were stained with antibody to PTEN (Dako, 
Carpinteria, CA). All histologies were centrally reviewed 
and all testing was performed in the Clinical Laboratory 
Improvement Amendment (CLIA) –certified Molecular 
Diagnostic Laboratory (MDL) at MD Anderson.
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